Daniel B. Costa

26.3k total citations · 6 hit papers
169 papers, 10.4k citations indexed

About

Daniel B. Costa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Daniel B. Costa has authored 169 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Pulmonary and Respiratory Medicine, 109 papers in Oncology and 42 papers in Molecular Biology. Recurrent topics in Daniel B. Costa's work include Lung Cancer Treatments and Mutations (140 papers), Lung Cancer Research Studies (57 papers) and Lung Cancer Diagnosis and Treatment (41 papers). Daniel B. Costa is often cited by papers focused on Lung Cancer Treatments and Mutations (140 papers), Lung Cancer Research Studies (57 papers) and Lung Cancer Diagnosis and Treatment (41 papers). Daniel B. Costa collaborates with scholars based in United States, Japan and Hong Kong. Daniel B. Costa's co-authors include Susumu Kobayashi, Mark S. Huberman, Hiroyuki Yasuda, Deepa Rangachari, Paul A. VanderLaan, Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, Kim-Son H. Nguyen and Keith D. Wilner and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Blood.

In The Last Decade

Daniel B. Costa

166 papers receiving 10.2k citations

Hit Papers

Clinical Features and Outcome of Patients With Non–Small-... 2009 2026 2014 2020 2009 2018 2011 2015 2011 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
    2009 1.5k citations Alice T. Shaw, Beow Y. Yeap et al. Journal of Clinical Oncology profile →
  2. Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
    2018 513 citations Geoffrey R. Oxnard, Daniel B. Costa et al. profile →
  3. CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
    2011 474 citations Daniel B. Costa, Susumu Kobayashi et al. Journal of Clinical Oncology profile →
  4. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
    2015 468 citations Daniel B. Costa, Alice T. Shaw et al. Journal of Clinical Oncology profile →
  5. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
    2011 451 citations Hiroyuki Yasuda, Susumu Kobayashi et al. profile →
  6. Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
    2015 348 citations Deepa Rangachari, Paul A. VanderLaan et al. Lung Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel B. Costa United States 49 8.4k 6.8k 3.6k 2.2k 712 169 10.4k
Robert C. Doebele United States 53 7.3k 0.9× 6.1k 0.9× 4.0k 1.1× 2.3k 1.1× 993 1.4× 250 10.4k
Sara M. Haserlat United States 9 7.0k 0.8× 6.2k 0.9× 3.7k 1.0× 2.3k 1.0× 632 0.9× 10 9.8k
Takayuki Kosaka Japan 32 6.5k 0.8× 5.6k 0.8× 3.8k 1.1× 1.8k 0.8× 726 1.0× 93 9.3k
Helena A. Yu United States 41 6.6k 0.8× 5.5k 0.8× 3.1k 0.9× 2.0k 0.9× 591 0.8× 195 8.4k
Sean Tracy United States 10 5.6k 0.7× 5.1k 0.8× 3.2k 0.9× 1.9k 0.8× 648 0.9× 20 8.3k
Ross A. Okimoto United States 20 8.1k 1.0× 7.3k 1.1× 4.9k 1.4× 2.7k 1.2× 868 1.2× 33 12.1k
Caicun Zhou China 39 6.8k 0.8× 6.4k 0.9× 2.6k 0.7× 1.6k 0.7× 433 0.6× 136 8.9k
Katerina Politi United States 38 7.4k 0.9× 7.2k 1.1× 5.5k 1.6× 2.8k 1.3× 758 1.1× 113 12.0k
Rafał Dziadziuszko Poland 44 6.3k 0.7× 5.8k 0.9× 2.7k 0.8× 1.8k 0.8× 557 0.8× 290 9.0k
Claire Watkins United Kingdom 21 7.8k 0.9× 7.5k 1.1× 2.9k 0.8× 2.1k 1.0× 553 0.8× 42 11.0k

Countries citing papers authored by Daniel B. Costa

Since Specialization
Citations

This map shows the geographic impact of Daniel B. Costa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel B. Costa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel B. Costa more than expected).

Fields of papers citing papers by Daniel B. Costa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel B. Costa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel B. Costa. The network helps show where Daniel B. Costa may publish in the future.

Co-authorship network of co-authors of Daniel B. Costa

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel B. Costa. A scholar is included among the top collaborators of Daniel B. Costa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel B. Costa. Daniel B. Costa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fujii, Masanori, Ikei S. Kobayashi, Vivian Ho, et al.. (2024). Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer. Cell Death and Disease. 15(8). 7 indexed citations
2.
Gunturu, Krishna S., Hollis Viray, Andrew J. Piper‐Vallillo, et al.. (2024). Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Lung Cancer. 198. 108023–108023. 1 indexed citations
3.
Costa, Daniel B., et al.. (2024). Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer. Lung Cancer. 194. 107885–107885. 6 indexed citations
4.
5.
Akanuma, Naoki, Ikei S. Kobayashi, Eunyoung Heo, et al.. (2023). TIP60 is required for tumorigenesis in non‐small cell lung cancer. Cancer Science. 114(6). 2400–2413. 14 indexed citations
6.
Kobayashi, Ikei S., Hollis Viray, Deepa Rangachari, et al.. (2023). The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports. 5(1). 100614–100614. 6 indexed citations
7.
Rudin, Charles M., Andrés Cervantes, Afshin Dowlati, et al.. (2023). Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. ESMO Open. 8(2). 101160–101160. 8 indexed citations
8.
9.
Academia, Emmeline C., Hollis Viray, Deepa Rangachari, et al.. (2023). EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates. Translational Lung Cancer Research. 12(7). 1590–1610. 16 indexed citations
10.
Cooper, Alissa J., Yoshihisa Kobayashi, Dewey Kim, et al.. (2020). Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(15). 4072–4079. 14 indexed citations
11.
VanderLaan, Paul A., Deepa Rangachari, & Daniel B. Costa. (2020). The rapidly evolving landscape of biomarker testing in non–small cell lung cancer. Cancer Cytopathology. 129(3). 179–181. 19 indexed citations
12.
Udagawa, Hibiki, Akihiro Ohashi, Naomi Abe, et al.. (2019). TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Molecular Cancer Research. 17(11). 2233–2243. 55 indexed citations
13.
Jorge, Susan E., Antonio R. Lucena‐Araujo, Hiroyuki Yasuda, et al.. (2018). EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clinical Cancer Research. 24(24). 6548–6555. 51 indexed citations
14.
Pennell, Nathan A., Joel W. Neal, Jamie E. Chaft, et al.. (2018). SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 37(2). 97–104. 137 indexed citations
15.
Rudin, Charles M., Andrés Cervantes, Afshin Dowlati, et al.. (2018). MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S407–S407. 26 indexed citations
16.
Yanagita, Masahiko, Amanda J. Redig, Cloud P. Paweletz, et al.. (2016). A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clinical Cancer Research. 22(24). 6010–6020. 92 indexed citations
17.
Nakayama, Sohei, Natasha Sng, Julián Carretero, et al.. (2014). β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations. Cancer Research. 74(20). 5891–5902. 72 indexed citations
18.
Klempner, Samuel J., et al.. (2013). Safety of Cupping During Bevacizumab Therapy. The Journal of Alternative and Complementary Medicine. 19(8). 729–731. 4 indexed citations
19.
Kobayashi, Susumu, Alexandra S. Bailey, Sohei Nakayama, et al.. (2012). Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology. 8(1). 118–122. 171 indexed citations
20.
Shaw, Alice T., Beow Y. Yeap, Mari Mino–Kenudson, et al.. (2009). Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK. Journal of Clinical Oncology. 27(26). 4247–4253. 1463 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert C. Doebele Breakdown of academic impact, for papers by Sara M. Haserlat Breakdown of academic impact, for papers by Takayuki Kosaka Breakdown of academic impact, for papers by Helena A. Yu Breakdown of academic impact, for papers by Sean Tracy Breakdown of academic impact, for papers by Ross A. Okimoto Breakdown of academic impact, for papers by Caicun Zhou Breakdown of academic impact, for papers by Katerina Politi Breakdown of academic impact, for papers by Rafał Dziadziuszko Breakdown of academic impact, for papers by Claire Watkins
Rankless by CCL
2026